Dongkook Pharmaceutical Co., Ltd.
Quick facts
Marketed products
- DKF-306 · Other
Phase 3 pipeline
- DKF-313 · Unknown
DKF-313 is a small molecule that targets the molecular target. - DKF-MA102 · Cardiovascular
DKF-MA102 is a small molecule drug that targets the molecular target.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Dongkook Pharmaceutical Co., Ltd. portfolio CI brief
- Dongkook Pharmaceutical Co., Ltd. pipeline updates RSS
Frequently asked questions about Dongkook Pharmaceutical Co., Ltd.
What are Dongkook Pharmaceutical Co., Ltd.'s marketed drugs?
Top marketed products include DKF-306.
What is Dongkook Pharmaceutical Co., Ltd.'s pipeline?
Dongkook Pharmaceutical Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include DKF-313, DKF-MA102.
Related
- DKF-306 · Other
- Sector hub: All tracked pharma companies